Intel has given back another leg of its historic rally, falling 12.6% on the week to $107.93, yet analysts are still scrambling to raise targets — a dynamic that tells you everything about how dislocated this stock remains.
The pace of analyst upgrades is striking given what the stock has already done. On June 1 alone, Barclays lifted its target from $65 to $100 (maintaining Equal-Weight), and Wells Fargo moved from $85 to $110 (also Equal-Weight) — both firms acknowledging the move while stopping well short of endorsing it. Mizuho nudged to $128 from $124, neutral. The mean target now stands at $88.71. Intel at $107.93 is still trading 22% above that consensus, even after a week that erased nearly 13%. That premium narrowed sharply from the 29% gap flagged in the June 1 note — but it hasn't closed. The broad Street posture remains deeply cautious: the vast majority of coverage is Hold-equivalent, with only a handful of buys. Citigroup's $130 target and Benchmark's $140, both raised May 18, are now the only analyst calls above where the stock is trading.
The valuation backdrop reinforces the caution. The PE multiple has compressed from the near-97x extreme noted in the May 27 note, but at 84x it still prices in a dramatic earnings recovery that hasn't yet arrived. EV/EBITDA has eased too, down roughly one turn over the past month to 25.8x. The EV/EBIT score ranks in the 3rd percentile — the quality and earnings-power side of Intel's story remains as thin as it has been all year. Against that, the 90-day EPS momentum factor sits at the 97th percentile, meaning forward estimates are moving sharply higher even if the base is distorted. Bulls point to Intel Foundry's medium-term optionality and the possibility of an AI data-centre chip by year-end. Bears note the foundry business isn't expected to reach profitability before 2027, and that Nvidia's Computex PC chip announcement — the catalyst behind the June 1 sell-off — means Intel is now fighting a two-front war in its legacy market as well.
Short positioning offers no particular tension this week. Short interest ticked up 4.6% on the week to 2.9% of free float — a modest rebuild, but far from an aggressive directional bet. Availability in the lending market is effectively unconstrained, with the ratio of shares available to borrow running at more than 7,600% relative to shares already lent — there is no squeeze pressure whatsoever. Cost to borrow is 0.49%, barely above the risk-free rate. The ORTEX short score is 30.7, unchanged over the past ten days, and the put/call ratio at 1.04 is running slightly below its 20-day average of 1.09, a full standard deviation lighter than the recent norm. That's not a defensive options setup — if anything, the hedging that was present in mid-May has faded even as the stock fell.
One insider data point worth noting: CFO David Zinsner sold 18,353 shares on June 1 at $109.82, raising just over $2 million. That followed a smaller open-market sale by an EVP on May 29. Neither transaction is large enough to read as a directional signal, and the 90-day net figure shows a positive net across all insiders of about $9.8 million — the bulk of which reflects a mix of awards and small secondary sells rather than a clean insider-buy thesis. Institutional holders, meanwhile, show BlackRock and Capital Research both adding modestly in April, while the base is broadly stable.
The stock is down 12.6% on the week while closest peer AMD gained 3.5% and Micron added 18.8%. That divergence keeps Intel firmly as the group's laggard despite its one-month gains. Q2 results are due July 23 — until then, the conversation is less about what Intel will earn and more about whether the Street catches up to the stock or the stock finally catches down to the Street.
See the live data behind this article on ORTEX.
Open INTC on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
